Crossmark

A randomized, double-blind, placebo-controlled trial of olanzapine versus placebo plus ondansetron and dexamethasone for antiemetic prophylaxis in patients receiving oxaliplatin-, irinotecan-, or carboplatin-based chemotherapy

Crossref DOI link: https://doi.org/10.1007/s00520-026-10490-8

Published Online: 2026-02-24

Published Print: 2026-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Harikul, Warangkana

Nimmannit, Akarin

Laocharoenkeat, Apirom

Phisalprapa, Pochamana

Kositamongkol, Chayanis

Thongkijpreecha, Phurita

Ithimakin, Suthinee
Funding

Funding for this research was provided by:

Siriraj Research Development Fund (Managed by Routine to Research: R2R), Mahidol University ((IO) R016835007)

Mahidol University
License Information

Text and Data Mining valid from 2026-02-24

Version of Record valid from 2026-02-24
More Information

Article History

Received: 22 September 2025

Accepted: 19 February 2026

First Online: 24 February 2026

Declarations

:

: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Siriraj Hospital, Mahidol University (Protocol No. 811/2567 (IRB3)/COA No. Si849/2024).

: All participants provided informed consent to participate in this study.

: All participants provided consent for publication of anonymized data.

: Written informed consent was obtained from all individual participants included in the study.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below